Limits...
Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China.

Richeldi L, Rubin AS, Avdeev S, Udwadia ZF, Xu ZJ - BMC Med (2015)

Bottom Line: It is estimated that a large number of IPF patients reside in BRIC countries (Brazil, Russia, India, and China) given their overall total population of approximately 3 billion inhabitants.Nevertheless, the limited availability of chest imaging in BRIC countries is considered a chief obstacle to diagnosis, since high-resolution computed tomography of the chest is the key diagnostic test for IPF.Further, obtaining reliable lung function tests and providing treatment access is difficult in the more rural areas of these countries.

View Article: PubMed Central - PubMed

Affiliation: Southampton Respiratory Biomedical Research Unit, Mailpoint 813, LE75 E Level, South Academic Block, University Hospital Southampton NHS Foundation Trust, Southampton, SO16 6YD, UK. l.richeldi@soton.ac.uk.

ABSTRACT
Idiopathic pulmonary fibrosis (IPF), the prototype of interstitial lung diseases, has the worst prognosis and is the only interstitial lung disease for which approved pharmacological treatments are available. Despite being considered a rare disease, IPF patients pose major challenges to both physicians and healthcare systems. It is estimated that a large number of IPF patients reside in BRIC countries (Brazil, Russia, India, and China) given their overall total population of approximately 3 billion inhabitants. Nevertheless, the limited availability of chest imaging in BRIC countries is considered a chief obstacle to diagnosis, since high-resolution computed tomography of the chest is the key diagnostic test for IPF. Further, obtaining reliable lung function tests and providing treatment access is difficult in the more rural areas of these countries. However, IPF might represent an opportunity for BRIC countries: the exponentially increasing demand for the enrollment of IPF patients in clinical trials of new drugs is predicted to face a shortage of patients - BRIC countries may thus play a crucial role in advancing towards a cure for IPF.

No MeSH data available.


Related in: MedlinePlus

The proportion of physicians who prescribed each of the specified treatments in patients diagnosed with idiopathic pulmonary fibrosis
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4581420&req=5

Fig5: The proportion of physicians who prescribed each of the specified treatments in patients diagnosed with idiopathic pulmonary fibrosis

Mentions: More than 90 % of IPF patients in Russia receive pharmacological therapy. The most commonly initiated therapies are oral corticosteroids (56 %), immunosuppressants (azathioprine or cyclophosphamide; 11 %), N-acetylcysteine (83 %), long-term oxygen therapy (89 %), anti-reflux agents (72 %), and pirfenidone (5 %; Fig. 5). If oral corticosteroids are prescribed, doses in the majority of centers are low (10–20 mg of prednisolone daily). Pirfenidone and nintedanib are not yet registered in Russia, and therefore their administration is possible only in patients who have the opportunity to obtain the drugs abroad.Fig. 5


Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China.

Richeldi L, Rubin AS, Avdeev S, Udwadia ZF, Xu ZJ - BMC Med (2015)

The proportion of physicians who prescribed each of the specified treatments in patients diagnosed with idiopathic pulmonary fibrosis
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4581420&req=5

Fig5: The proportion of physicians who prescribed each of the specified treatments in patients diagnosed with idiopathic pulmonary fibrosis
Mentions: More than 90 % of IPF patients in Russia receive pharmacological therapy. The most commonly initiated therapies are oral corticosteroids (56 %), immunosuppressants (azathioprine or cyclophosphamide; 11 %), N-acetylcysteine (83 %), long-term oxygen therapy (89 %), anti-reflux agents (72 %), and pirfenidone (5 %; Fig. 5). If oral corticosteroids are prescribed, doses in the majority of centers are low (10–20 mg of prednisolone daily). Pirfenidone and nintedanib are not yet registered in Russia, and therefore their administration is possible only in patients who have the opportunity to obtain the drugs abroad.Fig. 5

Bottom Line: It is estimated that a large number of IPF patients reside in BRIC countries (Brazil, Russia, India, and China) given their overall total population of approximately 3 billion inhabitants.Nevertheless, the limited availability of chest imaging in BRIC countries is considered a chief obstacle to diagnosis, since high-resolution computed tomography of the chest is the key diagnostic test for IPF.Further, obtaining reliable lung function tests and providing treatment access is difficult in the more rural areas of these countries.

View Article: PubMed Central - PubMed

Affiliation: Southampton Respiratory Biomedical Research Unit, Mailpoint 813, LE75 E Level, South Academic Block, University Hospital Southampton NHS Foundation Trust, Southampton, SO16 6YD, UK. l.richeldi@soton.ac.uk.

ABSTRACT
Idiopathic pulmonary fibrosis (IPF), the prototype of interstitial lung diseases, has the worst prognosis and is the only interstitial lung disease for which approved pharmacological treatments are available. Despite being considered a rare disease, IPF patients pose major challenges to both physicians and healthcare systems. It is estimated that a large number of IPF patients reside in BRIC countries (Brazil, Russia, India, and China) given their overall total population of approximately 3 billion inhabitants. Nevertheless, the limited availability of chest imaging in BRIC countries is considered a chief obstacle to diagnosis, since high-resolution computed tomography of the chest is the key diagnostic test for IPF. Further, obtaining reliable lung function tests and providing treatment access is difficult in the more rural areas of these countries. However, IPF might represent an opportunity for BRIC countries: the exponentially increasing demand for the enrollment of IPF patients in clinical trials of new drugs is predicted to face a shortage of patients - BRIC countries may thus play a crucial role in advancing towards a cure for IPF.

No MeSH data available.


Related in: MedlinePlus